首页> 外文期刊>Journal of Medicinal Chemistry >Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2
【24h】

Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2

机译:吡咯酮衍生物作为趋化因子受体的细胞内变形调节剂:CC趋化因子受体1和2的选择性和双靶向抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

The recent crystal structures of CC chemokine receptors 2 and 9 (CCR2 and CCR9) have provided structural evidence for an allosteric, intracellular binding site. The high conservation of residues involved in this site suggests its presence in most chemokine receptors, including the close homologue CCR1. By using [H-3]CCR2-RA-[R], a high-affinity, CCR2 intracellular ligand, we report an intracellular binding site in CCR1, where this radioligand also binds with high affinity. In addition, we report the synthesis and biological characterization of a series of pyrrolone derivatives for CCR1 and CCR2, which allowed us to identify several high-affinity intracellular ligands, including selective and potential multitarget antagonists. Evaluation of selected compounds in a functional [S-35]GTP gamma S assay revealed that they act as inverse agonists in CCR1, providing a new manner of pharmacological modulation. Thus, this intracellular binding site enables the design of selective and multitarget inhibitors as a novel therapeutic approach.
机译:最近CC趋化因子受体2和9(CCR2和CCR9)的晶体结构为变构细胞内结合位点提供了结构证据。本网站中涉及的残留物的高度守恒表明其在大多数趋化因子受体中的存在,包括密切同源性CCR1。通过使用[H-3] CCR2-Ra-[R],高亲和力,CCR2细胞内配体,我们在CCR1中报告了细胞内结合位点,其中该放射性配体也与高亲和力结合。此外,我们报告了CCR1和CCR2系列吡咯酮衍生物的合成和生物学特征,其使我们旨在鉴定几种高亲和力细胞内配体,包括选择性和潜在的多元拮抗剂。在功能性[S-35] GTPγ的测定中的选择化合物的评价显示它们在CCR1中作为反向激动剂,提供了一种新的药理学调节方式。因此,这种细胞内结合位点使得能够设计选择性和多元抑制剂作为一种新的治疗方法。

著录项

  • 来源
    《Journal of Medicinal Chemistry》 |2018年第20期|共16页
  • 作者单位

    Leiden Univ Div Drug Discovery &

    Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;

    Leiden Univ Div Drug Discovery &

    Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;

    Leiden Univ Div Drug Discovery &

    Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;

    Leiden Univ Div Drug Discovery &

    Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;

    Leiden Univ Div Drug Discovery &

    Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;

    Leiden Univ Div Drug Discovery &

    Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;

    Leiden Univ Div Drug Discovery &

    Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;

    Leiden Univ Div Drug Discovery &

    Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;

    Leiden Univ Div Drug Discovery &

    Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;

    Leiden Univ Div Drug Discovery &

    Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;

    Leiden Univ Div Drug Discovery &

    Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;

    Leiden Univ Div Drug Discovery &

    Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;

    Leiden Univ Div Drug Discovery &

    Safety Leiden Acad Ctr Drug Res POB 9502 NL-2300 RA Leiden Netherlands;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号